Lemon Medical offers viral and bacterial filters to protect patients, medical personnel, and diagnostic instruments from cross contamination during cardiorespiratory function testing

laboratory

Lemon Medical offers non-invasive diagnostic systems to detect, classify and manage cardiorespiratory disease. (Credit: Belova59 from Pixabay)

Altus Capital Partners portfolio company MGC Diagnostics has acquired German medical technology company Lemon Medical for an disclosed sum.

Based in Hammelburg, Lemon Medical is involved in the designing, development, production and supplying of single-patient use disposables.

Altus Capital Partners co-founder and senior partner Greg Greenberg said: “MGC Diagnostics is excited to further strengthen its in-house manufacturing capabilities, product offering, and European presence through this acquisition of Lemon.”

Lemon Medical’s product portfolio consists of viral and bacterial filters to protect patients, medical personnel, and diagnostic instruments from cross contamination during cardiorespiratory function testing.

According to the company, the usage of these products is significantly increasing due to the Covid pandemic and patient safety components are now required across the globe.

Lemon Medical is also engaged in the development, manufacturing and marketing of non-invasive diagnostic systems to detect, classify and manage cardiorespiratory disease.

MGC CEO Todd Austin said: “Following an exhaustive evaluation of the cardiorespiratory disposable filter market, MGC Diagnostics identified Lemon Medical, and its founder, Alfred Albert, as the ideal partner.

“This is another strategic acquisition for MGC Diagnostics, providing our own source of disposables as well as a significant footprint in the German market, one of the top cardiorespiratory scientific communities in the world.”

Based in Saint Paul, Minnesota, MGC Diagnostics develops, produces and sells non-invasive diagnostic systems to detect, classify and manage cardiorespiratory disease.

In November 2018, Altus Capital acquired US-based privately-held spinal device company ChoiceSpine, which offers spinal implants, instrumentation and biologies for surgical treatment of complex spine disorders.